ライフサイエンスコーパス: platelet-rich plasma

1 donor's blood samples (both whole blood and platelet-rich plasma).

2 imilar to that observed in vitro using mouse platelet rich plasma.

3 bility to inhibit ADP-induced aggregation in platelet-rich plasma.

4 counts for approximately 20% of total VWF in platelet-rich plasma.

5 DP-induced aggregation of human platelets in platelet-rich plasma.

6 nic acid-induced platelet aggregation in rat platelet-rich plasma.

7 ntent of anandamide in either macrophages or platelet-rich plasma.

8 ergizes with soluble collagen in aggregating platelet-rich plasma.

9 er the stent and was sprayed with autologous platelet-rich plasma adhesive gel.

10 RPAI-1 inhibits in vitro the ADP-dependent platelet-rich plasma aggregation by collagen (COLL), TRA

11 RPAI-1 inhibits human platelet-rich plasma aggregation triggered by low concen

12 ibition of aggregation of human platelets in platelet rich plasma, an IC50 of 6.8 nM for the inhibiti

13 orn trypsin inhibitor-treated whole blood or platelet rich plasma and subsequent array scanning via a

14 togenous bone and anorganic bovine bone with platelet-rich plasma and a bioabsorbable collagen membra

15 telet aggregation in response to collagen in platelet-rich plasma and firm adhesion on VWF under arte

16 antiplatelet activity both in vitro in human platelet-rich plasma and in vivo in mice.

17 Platelet-rich plasma and microneedling have been investi

18 arkedly enhanced thrombin generation in both platelet-rich plasma and platelet-poor plasma, indicatin

19 ysiologically relevant conditions such as in platelet-rich plasma and whole blood.

20 ibition of platelet aggregation in the human platelet rich plasma assay with IC(5)(0) values below 50

21 hat fails to inhibit platelet aggregation in platelet-rich plasma, blocked the inhibitory effect of t

22 Also, in CypD-deficient platelet-rich plasma, clot retraction was altered.

23 llograft (ADM) to that of a CPT plus ADM and platelet-rich plasma (CPT/PRP) 4 months post-surgically.

24 This study evaluates the influence of platelet-rich plasma derived from bone marrow aspirate (

25 inced the Canadian Blood Services to abandon platelet-rich-plasma-derived concentrates.

26 groups: demineralized freeze dried bone with platelet-rich plasma (DFDB + PRP), DFDB alone, and no tr

27 se of autologous fibrin membrane and the eye platelet-rich plasma (E-PRP) clot could be considered as

28 ncoated stents were then immersed in porcine platelet-rich plasma for two min and the platelet cyclic

29 PT was performed ex vivo by mixing platelet-rich plasma from blood sampling performed at ba

30 Unlike fibrinogen-deficient mice, platelet-rich plasma from Fib(AEK) mice supported normal

31 Blood or platelet-rich plasma from healthy volunteers stimulated

32 ated primary glomerular endothelial cells to platelet-rich plasma from patients, or patient platelet-

33 hibited when compared to the wild-type using platelet-rich plasma from the principal donor, but adhes

34 l of PVR in which cells were coinjected with platelet-rich plasma into the vitreous.

35 Platelet-rich plasma obtained from healthy (PRP) or tumo

36 of blood microparticles (MPs) obtained from platelet-rich plasma of healthy individuals was characte

37 anufacture of whole-blood-derived platelets (platelet-rich plasma or buffy coat intermediate steps) r

38 Shear-induced GPVI shedding also occurred in platelet-rich plasma or washed platelets isolated from a

39 Human-citrated platelet-rich plasma or washed platelets were subjected

40 PMPs were isolated from platelet-rich plasma or were generated by activating was

41 nts or sample volumes can be used, either of platelet-rich plasma or whole blood from human subjects

42 r in agonist-induced aggregation measured in platelet-rich plasma or with washed platelets.

43 ormed in platelets, platelet microparticles, platelet-rich plasma, platelet-poor plasma, and serum.

44 platelet aggregation as measured in a human platelet rich plasma (PRP) assay.

45 th PMN and PMN-RBC combinations suspended in platelet rich plasma (PRP) than in platelet poor plasma

46 played inhibition of platelet aggregation in platelet rich plasma (PRP) with an IC(50) value of 53 nM

47 In platelet rich plasma (PRP), progressive APC resistance w

48 ADP stimulated human platelet aggregation in platelet rich plasma (PRP).

49 ration time (TGT) coagulation assay in human platelet rich plasma (PRP).

50 as to evaluate the regenerative influence of platelet-rich plasma (PRP) added to xenogenic bone graft

51 ion of CD62P by wild-type mouse platelets in platelet-rich plasma (PRP) and caused their secretion of

52 procoagulant potential of human platelets in platelet-rich plasma (PRP) and in purified systems.

53 lyze the content and specific effect of both platelet-rich plasma (PRP) and platelet-poor plasma (PPP

54 The comparison used platelet-rich plasma (PRP) and platelet-poor plasma (PPP

55 Platelet-rich plasma (PRP) and platelet-poor plasma (PPP

56 The antimicrobial activities of platelet-rich plasma (PRP) and related plasma preparatio

57 nhanced by 127% (P < 0.001) in study patient platelet-rich plasma (PRP) compared to control PRP and c

58 Platelet-rich plasma (PRP) consists of platelet-derived

59 Platelet-rich plasma (PRP) contains a number of biologic

60 lcium sulfate hemihydrate (MGCSH) mixed with platelet-rich plasma (PRP) for extraction socket preserv

61 Platelet-rich plasma (PRP) from normal mice was able to

62 Platelet-rich plasma (PRP) harbors growth factors identi

63 Platelet-rich plasma (PRP) has been promoted as a surgic

64 e mineral (NBM) with and without addition of platelet-rich plasma (PRP) has been shown to result in s

65 ch surrounding intra-articular injections of platelet-rich plasma (PRP) has not produced clear eviden

66 hput microfluidic removal of leukocytes from platelet-rich plasma (PRP) in a continuous flow regime.

67 of autologous platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) in the treatment of intrabony

68 al benefits provided by the incorporation of platelet-rich plasma (PRP) into a regenerative protocol

69 Platelet-rich plasma (PRP) is a milieu of bioactive fact

70 Platelet-rich plasma (PRP) is used to stimulate the repa

71 Platelet-rich plasma (PRP) is widely used for many clini

72 Platelet-rich plasma (PRP) promotes regeneration of bone

73 Calibrated thrombin assays using platelet-rich plasma (PRP) showed that tissue factor-tri

74 of recalcified platelet-free plasma (PFP) or platelet-rich plasma (PRP) supplemented with corn trypsi

75 al intrabony defects, the benefits of adding platelet-rich plasma (PRP) to a bone replacement graftin

76 plored through a spectrophotometric assay on platelet-rich plasma (PRP) treated with the thromboxane

77 Citrated platelet-rich plasma (PRP) turbidimetry is used for asse

78 Platelet-rich plasma (PRP) was prepared from 28 healthy

79 Blood samples were collected and platelet-rich plasma (PRP) was prepared.

80 aggregation tests (PATs) were performed with platelet-rich plasma (PRP), a shorter lag time was measu

81 Platelet-rich plasma (PRP), an autologous derivative of

82 A combination of platelet-rich plasma (PRP), bovine porous bone mineral (

83 Platelet-rich plasma (PRP), containing autologous growth

84 tomorphometrically analyzes the influence of platelet-rich plasma (PRP), low-level laser therapy (LLL

85 ractionated to yield red blood cells (RBCs), platelet-rich plasma (PRP), platelet-poor plasma (PPP),

86 Recent reports suggest that platelet-rich plasma (PRP), presumably high in levels of

87 In human platelet-rich plasma (PRP), RvE1 selectively blocked bot

88 ng of recombinant human TPO (rhTPO) to human platelet-rich plasma (PRP), washed platelets (WP), and c

89 activation occurred during leukodepletion of platelet-rich plasma (PRP).

90 FXI-depleted plasma and markedly enhanced in platelet-rich plasma (PRP).

91 was modified with PAR4-AP and incubated with platelet-rich plasma (PRP).

92 PVR was induced by the injection of RCFs and platelet-rich plasma (PRP).

93 specifically in VAT, in addition to elevated platelet-rich-plasma (PRP) NPY, compared to control fema

94 12-hydroxyeicosatetraenoic acid to P-12LO-/- platelet-rich plasma rescues the hyperresponsive phenoty

95 Platelet aggregation assays with citrated platelet-rich plasma reveal that the primary and seconda

96 d at baseline in increasing proportions with platelet-rich plasma sampled 4 hours after loading dose.

97 ation, including the use of gene therapy and platelet-rich plasma scaffolds, are also discussed.

98 ing, hydrogel-coated PVC membranes soaked in platelet-rich plasma showed less adhesion and activation

99 Platelet-rich plasma showed markedly higher levels of mi

100 ctor Xa-inhibited (250 nM apixaban), diluted platelet rich plasma that had been loaded with the calci

101 ld be prevented by simply reducing the pH of platelet-rich plasma to about 6.5 prior to centrifugatio

102 Using gel-filtered platelets derived from platelet-rich plasma treated with alpha-tocopherol (500

103 r, second-wave aggregation induced by MDC in platelet-rich plasma was inhibited by aspirin, ADP scave

104 Platelet-rich plasma was obtained for aggregometry induc

105 Differential levels of endotoxin in platelet-rich plasma were detected using the limulus ame

106 the coagulation cascade in platelet poor or platelet-rich plasma, when activation was initiated by t

107 However, in platelet-rich plasma, where formation of both Tx and PGD

108 roparticles in megakaryocyte cultures and in platelet-rich plasma, which are predominantly derived fr

109 atelets derived from apheresis compared with platelet-rich plasma whole-blood-derived platelets.

110 ma cofactor, because a 35-hour incubation of platelet-rich plasma with 125I-factor V showed no specif